Literature DB >> 15931079

The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking.

Jennifer M Bossert1, Robert F Busch, Sarah M Gray.   

Abstract

In humans, drug-associated stimuli can provoke heroin relapse during abstinence. In rats, cues paired with heroin self-administration reinstate heroin seeking in a relapse model. The neurobiological mechanisms involved in this reinstatement, however, are largely unknown. Here, we determined the effect of LY379268, an mGluR2/3 agonist that decreases evoked glutamate release, on cue-induced reinstatement of heroin seeking. Systemic injections of LY379268 attenuated reinstatement of heroin seeking induced by exposure to a discrete tone-light cue that was previously paired with heroin infusions during self-administration training. In contrast, LY379268 had no effect on heroin self-administration. Results indicate that glutamate plays an important role in cue-induced reinstatement of heroin seeking and suggest that mGluR2/3 agonists should be considered for the treatment of opiate relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15931079     DOI: 10.1097/00001756-200506210-00026

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  45 in total

1.  New operant model of reinstatement of food-seeking behavior in mice.

Authors:  Elena Martín-García; Aurelijus Burokas; Elzbieta Kostrzewa; Agnieszka Gieryk; Michal Korostynski; Barbara Ziolkowska; Barbara Przewlocka; Ryszard Przewlocki; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2010-12-14       Impact factor: 4.530

2.  Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR 2/3 agonist LY379268 and increased functional activity of mGluR 2/3 in rats with a history of ethanol dependence.

Authors:  Peter R Kufahl; Rémi Martin-Fardon; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2011-08-31       Impact factor: 7.853

3.  Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking.

Authors:  Jennifer M Bossert; Sarah M Gray; Lin Lu; Yavin Shaham
Journal:  Neuropsychopharmacology       Date:  2005-12-07       Impact factor: 7.853

Review 4.  From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders.

Authors:  Jane B Acri; Alan J Cross; Phil Skolnick
Journal:  Psychopharmacology (Berl)       Date:  2016-12-20       Impact factor: 4.530

5.  Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core.

Authors:  B M Siemsen; C M Reichel; K C Leong; C Garcia-Keller; C D Gipson; S Spencer; J A McFaddin; K N Hooker; P W Kalivas; M D Scofield
Journal:  Neuroscience       Date:  2019-03-26       Impact factor: 3.590

Review 6.  Future pharmacological treatments for substance use disorders.

Authors:  Ariadna Forray; Mehmet Sofuoglu
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

Review 7.  The Opioid-Addicted Tetrapartite Synapse.

Authors:  Anna Kruyer; Vivian C Chioma; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2019-06-13       Impact factor: 13.382

8.  Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats.

Authors:  Jun-Tao Gao; Chloe J Jordan; Guo-Hua Bi; Yi He; Hong-Ju Yang; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2018-10-03       Impact factor: 7.853

Review 9.  Biological substrates of addiction.

Authors:  Max E Joffe; Carrie A Grueter; Brad A Grueter
Journal:  Wiley Interdiscip Rev Cogn Sci       Date:  2014-01-14

10.  Clavulanic acid reduces rewarding, hyperthermic and locomotor-sensitizing effects of morphine in rats: a new indication for an old drug?

Authors:  Joseph A Schroeder; Nicholas G Tolman; Faye F McKenna; Kelly L Watkins; Sara M Passeri; Alexander H Hsu; Brittany R Shinn; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.